Literature DB >> 34022927

Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.

Sammer Diab1,2, Shemy Carasso3,4, Mattan Arazi5, Leonid Sternik5,6, Ehud Raanani5,6, Erez Kachel1,2, Liza Grosman-Rimon1, Amjad Shalabi1, Offer Amir2,7,8.   

Abstract

BACKGROUND: Management of patients treated with Ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis. The aim of the study was to compare bleeding complications in patients treated with ticagrelor combined with acetylsalicylic acid (ASA) versus ASA alone until 1 day before surgery.
METHODS: Bleeding complications, defined as the composite of red blood cell transfusion ≥1000 ml, chest drainage ≥2000 ml, and bleeding requiring surgical re-exploration, were compared in 161 patients, with 101 on preoperative acetylsalicylic acid (ASA) alone (group A) and 65 on ticagrelor + ASA (group B).
RESULTS: There were no differences in bleeding complications between the two groups (26% vs. 27% in group A and B, respectively), with similar chest drainage in the first 24 h (569 ± 393 ml and 649 ± 427 ml, respectively).
CONCLUSIONS: Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that continued management with ticagrelor until surgery may be safe.

Entities:  

Keywords:  Acute coronary syndrome; Bleeding; Coronary artery bypass graft; Coronary artery bypass graft surgery; Dual anti platelet therapy; Ticagrelor

Year:  2021        PMID: 34022927     DOI: 10.1186/s13019-021-01521-y

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  34 in total

1.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

2.  Bleeding risk and incidence in real world percutaneous coronary intervention patients with ticagrelor.

Authors:  Ivan Subiakto; Muhammad Asrar ul Haq; William J Van Gaal
Journal:  Heart Lung Circ       Date:  2014-10-30       Impact factor: 2.975

3.  Prehospital ticagrelor in ST-segment elevation myocardial infarction.

Authors:  Gilles Montalescot; Arnoud W van 't Hof
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 4.  How to manage prasugrel and ticagrelor in daily practice.

Authors:  Fanny Bonhomme; Pierre Fontana; Jean-Luc Reny
Journal:  Eur J Intern Med       Date:  2014-02-12       Impact factor: 4.487

5.  2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  J Am Coll Cardiol       Date:  2014-09-23       Impact factor: 24.094

6.  Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.

Authors:  Emma C Hansson; Helena Rexius; Mikael Dellborg; Per Albertsson; Anders Jeppsson
Journal:  Eur J Cardiothorac Surg       Date:  2014-01-30       Impact factor: 4.191

7.  Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.

Authors:  James J DiNicolantonio; Fabrizio D'Ascenzo; Ales Tomek; Saurav Chatterjee; Asfandyar K Niazi; Giuseppe Biondi-Zoccai
Journal:  Int J Cardiol       Date:  2013-07-29       Impact factor: 4.164

8.  Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

Authors:  Dominick J Angiolillo; Michael S Firstenberg; Matthew J Price; Pradyumna E Tummala; Martin Hutyra; Ian J Welsby; Michele D Voeltz; Harish Chandna; Chandrashekhar Ramaiah; Miroslav Brtko; Louis Cannon; Cornelius Dyke; Tiepu Liu; Gilles Montalescot; Steven V Manoukian; Jayne Prats; Eric J Topol
Journal:  JAMA       Date:  2012-01-18       Impact factor: 56.272

9.  Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?

Authors:  Chantal L I Gielen; Eline F Bruggemans; Theo Stijnen; Jeroen Eikenboom; Giuseppe Tavilla; Anneke Brand; Robert J M Klautz
Journal:  Eur J Cardiothorac Surg       Date:  2015-08-06       Impact factor: 4.191

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

View more
  1 in total

Review 1.  Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.

Authors:  Marijana Matejic-Spasic; Kambiz Hassan; Matthias Thielmann; Stephan Geidel; Robert F Storey; Michael Schmoeckel; Harriet Adamson; Efthymios N Deliargyris; Daniel Wendt
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.